shutterstock_1396958150_pavel_kapysh-1
Pavel Kapysh / Shutterstock.com
10 September 2020AmericasSarah Morgan

Ruling opens door for Noven’s oestrogen patch generics

In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 September 2020   Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Americas
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.

More on this story

Big Pharma
4 September 2020   Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Americas
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.

More on this story

Big Pharma
4 September 2020   Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Americas
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.